

TABLE 41 Follow-up at the time point equivalent to 3 months after surgery: medications

| Medication | Randomised participants | | | | Preference participants | | | |
|--|-------------------------|-------------|---------------|---------------|-------------------------|-------------|---------------|---------------|
| | Surgical | | Medical | | Surgical | | Medical | |
| | ITT | PP | ITT | PP | ITT | PP | ITT | PP |
| Number randomised/allocated | 178 | 111 | 179 | 169 | 261 | 218 | 192 | 189 |
| Number of responders | 150 | 109 | 158 | 150 | 230 | 203 | 182 | 178 |
| PPIs, <i>n</i> (%) ^a | | | | | | | | |
| Any PPI | 47 (31.3) | 8 (7.3) | 140 (88.6) | 133 (88.7) | 41 (17.8) | 13 (6.4) | 167 (91.8) | 152 (84.9) |
| Omeprazole | 16 (10.7) | 5 (4.6) | 45 (28.5) | 45 (30.0) | 15 (6.5) | 3 (1.5) | 57 (31.3) | 57 (31.8) |
| Lansoprazole | 19 (12.7) | 3 (2.8) | 55 (34.8) | 54 (36.0) | 13 (5.7) | 7 (3.5) | 67 (36.8) | 64 (35.8) |
| Pantoprazole | 1 (0.7) | 0 (0.0) | 9 (5.7) | 8 (5.3) | 3 (1.3) | 2 (1.0) | 14 (7.7) | 14 (7.8) |
| Rabeprazole | 4 (2.7) | 1 (0.9) | 9 (5.7) | 9 (6.0) | 3 (1.3) | 0 (0.0) | 13 (7.1) | 13 (7.3) |
| Esomeprazole | 7 (4.7) | 1 (0.9) | 22 (13.9) | 21 (14.0) | 7 (3.0) | 3 (1.5) | 21 (11.5) | 21 (11.7) |
| H ₂ RAs, <i>n</i> (%) ^a | | | | | | | | |
| Any H ₂ RA | 1 (0.7) | 0 (0.0) | 12 (7.6) | 10 (6.7) | 4 (1.7) | 2 (1.0) | 14 (7.7) | 13 (7.3) |
| Ranitidine | 0 (0.0) | 0 (0.0) | 8 (5.1) | 8 (5.3) | 2 (0.9) | 1 (0.5) | 10 (5.5) | 9 (5.0) |
| Famotidine | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.5) | 1 (0.6) |
| Cimetidine | 1 (0.7) | 0 (0.0) | 1 (0.6) | 1 (0.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Nizatidine | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.5) | 1 (0.6) |
| Over-the-counter H ₂ RA | 0 (0.0) | 0 (0.0) | 4 (2.5) | 4 (2.7) | 2 (0.9) | 1 (0.5) | 3 (1.7) | 3 (1.7) |
| Prokinetics, <i>n</i> (%) ^a | | | | | | | | |
| Any prokinetic | 7 (4.7) | 3 (2.8) | 6 (3.8) | 5 (3.3) | 7 (3.0) | 6 (3.0) | 5 (2.7) | 4 (2.2) |
| Domperidone | 3 (2.0) | 1 (0.9) | 6 (3.8) | 5 (3.3) | 3 (1.3) | 2 (1.0) | 4 (2.2) | 3 (1.7) |
| Metoclopramide | 4 (2.7) | 2 (1.8) | 0 (0.0) | 0 (0.0) | 4 (1.7) | 4 (2.0) | 1 (0.5) | 1 (0.6) |
| Any reflux-related drug, <i>n</i> (%) ^a | 50 (33.3) | 10 (9.2) | 146 (92.4) | 139 (92.7) | 45 (19.6) | 17 (8.4) | 176 (96.7) | 161 (89.9) |
| Other prescribed drugs, <i>n</i> ^b | | | | | | | | |
| Alginates | 0 | 0 | 4 | 4 | 0 | 0 | 2 | 2 |
| Antispasmodics (e.g. dicycloverine) | 0 | 0 | 1 | 1 | 2 | 2 | 0 | 0 |
| Chelates (e.g. sucralfate) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

continued

TABLE 41 Follow-up at the time point equivalent to 3 months after surgery: medications (*continued*)

| Medication | Randomised participants | | | | Preference participants | | | |
|---------------------------|-------------------------|----|---------|----|-------------------------|----|---------|----|
| | Surgical | | Medical | | Surgical | | Medical | |
| | ITT | PP | ITT | PP | ITT | PP | ITT | PP |
| Other ulcer-healing drugs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mucogel | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Asilone | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-gastrointestinal | 1 | 1 | 0 | 0 | 2 | 1 | 1 | 1 |
| Anti-motility | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |

a Percentage is for responders completing the relevant section of the questionnaire.

b More than one prescription per person possible.

TABLE 42 Follow-up at the time point equivalent to 12 months after surgery: medications

| Medication | Randomised participants | | | | Preference participants | | | |
|--|-------------------------|--------------|---------------|---------------|-------------------------|--------------|---------------|---------------|
| | Surgical | | Medical | | Surgical | | Medical | |
| | ITT | PP | ITT | PP | ITT | PP | ITT | PP |
| Number randomised/allocated | 178 | 111 | 179 | 169 | 261 | 218 | 192 | 189 |
| Number of responders | 154 | 104 | 164 | 155 | 230 | 202 | 177 | 174 |
| PPIs, <i>n</i> (%) ^a | | | | | | | | |
| Any PPI | 56 (36.4) | 13 (12.5) | 142 (86.6) | 139 (89.7) | 42 (18.3) | 19 (9.4) | 156 (88.1) | 154 (88.5) |
| Omeprazole | 19 (12.3) | 6 (5.8) | 47 (28.7) | 45 (29.0) | 14 (6.1) | 4 (2.0) | 61 (34.5) | 60 (34.5) |
| Lansoprazole | 21 (13.6) | 2 (1.9) | 51 (31.1) | 50 (32.3) | 17 (7.4) | 12 (5.9) | 56 (31.6) | 5 (31.6) |
| Pantoprazole | 2 (1.3) | 1 (1.0) | 9 (5.5) | 9 (5.8) | 3 (1.3) | 1 (0.5) | 16 (9.0) | 16 (9.2) |
| Rabeprazole | 3 (1.9) | 1 (1.0) | 12 (7.3) | 12 (7.7) | 2 (0.9) | 0 (0.0) | 9 (5.1) | 9 (5.2) |
| Esomeprazole | 11 (7.1) | 3 (2.9) | 25 (15.2) | 25 (16.1) | 8 (3.5) | 3 (1.5) | 15 (8.5) | 15 (8.6) |
| H ₂ RAs, <i>n</i> (%) ^a | | | | | | | | |
| Any H ₂ RA | 4 (2.6) | 3 (2.9) | 9 (5.5) | 9 (5.8) | 5 (2.2) | 2 (1.0) | 13 (7.3) | 13 (7.5) |
| Ranitidine | 3 (1.9) | 2 (1.9) | 7 (4.3) | 7 (4.5) | 2 (0.9) | 0 (0.0) | 8 (4.5) | 8 (4.6) |
| Famotidine | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.6) | 1 (0.6) |
| Cimetidine | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Nizatidine | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Over-the-counter H ₂ RA | 1 (0.6) | 1 (1.0) | 2 (1.2) | 2 (1.3) | 3 (1.3) | 2 (1.0) | 5 (2.8) | 5 (2.9) |
| Prokinetics, <i>n</i> (%) ^a | | | | | | | | |
| Any prokinetic | 6 (3.9) | 2 (1.9) | 4 (2.4) | 4 (2.6) | 5 (2.2) | 4 (2.0) | 6 (3.4) | 5 (2.9) |
| Domperidone | 4 (2.6) | 1 (1.0) | 4 (2.4) | 4 (2.6) | 1 (0.4) | 0 (0.0) | 5 (2.8) | 4 (2.3) |
| Metoclopramide | 2 (1.3) | 1 (1.0) | 0 (0.0) | 0 (0.0) | 4 (1.7) | 4 (2.0) | 1 (0.6) | 1 (0.6) |
| Any reflux-related drug, <i>n</i> (%) ^a | 58 (37.7) | 15 (14.4) | 148 (90.2) | 144 (92.9) | 46 (20.0) | 22 (10.8) | 165 (93.2) | 163 (93.7) |
| Other prescribed drugs, <i>n</i> ^b | | | | | | | | |
| Alginates | 3 | 0 | 4 | 4 | 1 | 0 | 5 | 5 |
| Antispasmodics (e.g. dicycloverine) | 1 | 1 | 4 | 4 | 1 | 1 | 1 | 1 |
| Chelates (e.g. sucralfate) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other ulcer- healing drugs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mucogel | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Asilone | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-gastrointestinal | 2 | 2 | 6 | 5 | 4 | 4 | 3 | 3 |
| Anti-motility | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

a Percentage is for responders completing the relevant section of the questionnaire.

b More than one prescription per person possible.

TABLE 43 Follow-up at the time point equivalent to 2 years after surgery: medications

| Medication | Randomised participants | | | | Preference participants | | | |
|--|-------------------------|--------------|---------------|---------------|-------------------------|--------------|---------------|---------------|
| | Surgical | | Medical | | Surgical | | Medical | |
| | ITT | PP | ITT | PP | ITT | PP | ITT | PP |
| Number randomised/allocated | 178 | 111 | 179 | 169 | 261 | 218 | 192 | 189 |
| Number of responders | 128 | 86 | 142 | 136 | 203 | 182 | 156 | 153 |
| PPIs, <i>n</i> (%) ^a | | | | | | | | |
| Any PPI | 47 (36.7) | 13 (15.1) | 121 (85.2) | 119 (87.5) | 43 (21.2) | 29 (15.9) | 129 (82.7) | 128 (83.7) |
| Omeprazole | 17 (13.3) | 4 (4.7) | 43 (30.3) | 42 (30.9) | 11 (5.4) | 8 (4.4) | 48 (30.8) | 47 (30.7) |
| Lansoprazole | 17 (13.3) | 3 (3.5) | 39 (27.5) | 39 (28.7) | 15 (7.4) | 13 (7.1) | 42 (26.9) | 42 (27.5) |
| Pantoprazole | 1 (0.8) | 1 (1.2) | 6 (4.2) | 5 (3.7) | 2 (1.0) | 1 (0.5) | 12 (7.7) | 12 (7.8) |
| Rabeprazole | 4 (3.1) | 1 (1.2) | 12 (8.5) | 12 (8.8) | 3 (1.5) | 0 (0.0) | 6 (3.8) | 6 (3.9) |
| Esomeprazole | 8 (6.3) | 4 (4.7) | 20 (14.1) | 20 (14.7) | 9 (4.4) | 5 (2.7) | 14 (9.0) | 14 (9.2) |
| H ₂ RAs, <i>n</i> (%) ^a | | | | | | | | |
| Any H ₂ RA | 2 (1.6) | 1 (1.2) | 5 (3.5) | 5 (3.7) | 1 (0.5) | 0 (0.0) | 13 (8.3) | 13 (8.5) |
| Ranitidine | 2 (1.6) | 1 (1.2) | 4 (2.8) | 4 (2.9) | 1 (0.5) | 0 (0.0) | 12 (7.7) | 12 (7.8) |
| Famotidine | 0 (0.0) | 0 (0.0) | 1 (0.7) | 1 (0.7) | 0 (0.0) | 0 (0.0) | 1 (0.6) | 1 (0.7) |
| Cimetidine | 0 (0.0) | 0 (0.0) | 1 (0.7) | 1 (0.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Over-the-counter H ₂ RA | 1 (0.8) | 0 (0.0) | 2 (1.4) | 2 (1.5) | 2 (1.0) | 2 (1.1) | 2 (1.3) | 2 (1.3) |
| Prokinetics, <i>n</i> (%) ^a | | | | | | | | |
| Any prokinetic | 5 (3.9) | 4 (4.7) | 7 (4.9) | 6 (4.4) | 5 (2.5) | 3 (1.6) | 4 (2.6) | 4 (2.6) |
| Domperidone | 5 (3.9) | 4 (4.7) | 3 (2.1) | 3 (2.2) | 2 (1.0) | 0 (0.0) | 3 (1.9) | 3 (2.0) |
| Metoclopramide | 0 (0.0) | 0 (0.0) | 4 (2.8) | 3 (2.2) | 3 (1.5) | 3 (1.6) | 1 (0.6) | 1 (0.7) |
| Any reflux-related drug, <i>n</i> (%) ^a | 48 (37.5) | 14 (16.3) | 124 (87.3) | 122 (89.7) | 46 (22.7) | 30 (16.5) | 140 (89.7) | 139 (90.8) |
| Other prescribed drugs, <i>n</i> ^b | | | | | | | | |
| Alginates | 5 | 2 | 4 | 4 | 5 | 3 | 6 | 6 |
| Antispasmodics (e.g. dicycloverine) | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 |
| Chelates (e.g. sucralfate) | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Other ulcer-healing drugs | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Mucogel | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asilone | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-gastrointestinal | 1 | 0 | 0 | 0 | 3 | 3 | 5 | 5 |
| Anti-nausea | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
| Anti-motility | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Over the counter – not prescribed | 6 | 0 | 8 | 7 | 2 | 1 | 6 | 6 |

^a Percentage is for responders completing the relevant section of the questionnaire.

^b More than one prescription per person possible.

TABLE 44 Follow-up at the time point equivalent to 3 years after surgery: medications

| Medication | Randomised participants | | | | Preference participants | | | |
|--|-------------------------|--------------|---------------|---------------|-------------------------|--------------|---------------|---------------|
| | Surgical | | Medical | | Surgical | | Medical | |
| | ITT | PP | ITT | PP | ITT | PP | ITT | PP |
| Number randomised/allocated | 178 | 111 | 179 | 169 | 261 | 218 | 192 | 189 |
| Number of responders | 132 | 92 | 134 | 133 | 196 | 175 | 159 | 156 |
| PPIs, <i>n</i> (%) ^a | | | | | | | | |
| Any PPI | 50 (37.9) | 18 (19.6) | 112 (83.6) | 112 (84.2) | 47 (24.0) | 32 (18.3) | 129 (81.1) | 128 (82.1) |
| Omeprazole | 19 (14.4) | 8 (8.7) | 43 (32.1) | 43 (32.3) | 16 (8.2) | 9 (5.1) | 51 (32.1) | 50 (32.1) |
| Lansoprazole | 13 (9.8) | 1 (1.1) | 37 (27.6) | 37 (27.8) | 20 (10.2) | 16 (9.1) | 45 (28.3) | 45 (28.8) |
| Pantoprazole | 3 (2.3) | 3 (3.3) | 4 (3.0) | 4 (3.0) | 3 (1.5) | 3 (1.7) | 10 (6.3) | 10 (6.4) |
| Rabeprazole | 5 (3.8) | 2 (2.2) | 8 (6.0) | 8 (6.0) | 1 (0.5) | 0 (0.0) | 6 (3.8) | 6 (3.8) |
| Esomeprazole | 8 (6.1) | 5 (5.4) | 20 (14.9) | 20 (15.0) | 6 (3.1) | 4 (2.3) | 12 (7.5) | 12 (7.7) |
| H ₂ RAs, <i>n</i> (%) ^a | | | | | | | | |
| Any H ₂ RA | 2 (1.5) | 1 (1.1) | 2 (1.5) | 2 (1.5) | 2 (1.0) | 0 (0.0) | 10 (6.3) | 10 (6.4) |
| Ranitidine | 2 (1.5) | 1 (1.1) | 2 (1.5) | 2 (1.5) | 2 (1.0) | 0 (0.0) | 9 (5.7) | 9 (5.8) |
| Famotidine | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.6) | 1 (0.6) |
| Over-the-counter H ₂ RA | 1 (0.8) | 0 (0.0) | 2 (1.5) | 2 (1.5) | 6 (3.1) | 2 (1.1) | 4 (2.5) | 2 (1.3) |
| Prokinetics, <i>n</i> (%) ^a | | | | | | | | |
| Any prokinetic | 3 (2.3) | 2 (2.2) | 6 (4.5) | 6 (4.5) | 5 (2.6) | 2 (1.1) | 4 (2.5) | 4 (2.6) |
| Domperidone | 2 (1.5) | 2 (2.2) | 4 (3.0) | 4 (3.0) | 2 (1.0) | 0 (0.0) | 3 (1.9) | 3 (1.9) |
| Metoclopramide | 1 (0.8) | 0 (0.0) | 2 (1.5) | 2 (1.5) | 3 (1.5) | 2 (1.1) | 1 (0.6) | 1 (0.6) |
| Any reflux-related drug, <i>n</i> (%) ^a | 51 (38.6) | 18 (19.6) | 113 (84.3) | 113 (85.0) | 47 (24.0) | 32 (18.3) | 135 (84.9) | 134 (85.9) |
| Other prescribed drugs, <i>n</i> ^b | | | | | | | | |
| Alginates | 9 | 4 | 12 | 12 | 10 | 3 | 12 | 6 |
| Antispasmodics (e.g. dicycloverine) | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 |
| Chelates (e.g. sucralfate) | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Other ulcer-healing drugs | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Mucogel | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Asilone | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-gastrointestinal | 2 | 2 | 6 | 6 | 1 | 3 | 1 | 5 |
| Anti-nausea | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anti-motility | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Over the counter – not prescribed | 0 | 0 | 1 | 1 | 2 | 1 | 2 | 6 |

a Percentage is for responders completing the relevant section of the questionnaire.

b More than one prescription per person possible.

TABLE 45 Follow-up at the time point equivalent to 4 years after surgery: medications

| Medication | Randomised participants | | | | Preference participants | | | |
|--|-------------------------|--------------|---------------|---------------|-------------------------|--------------|---------------|---------------|
| | Surgical | | Medical | | Surgical | | Medical | |
| | ITT | PP | ITT | PP | ITT | PP | ITT | PP |
| Number randomised/allocated | 178 | 111 | 179 | 169 | 261 | 218 | 192 | 189 |
| Number of responders | 126 | 88 | 129 | 127 | 168 | 152 | 142 | 139 |
| PPIs, <i>n</i> (%) ^a | | | | | | | | |
| Any PPI | 52 (41.3) | 21 (23.9) | 104 (80.6) | 104 (81.9) | 42 (25.0) | 30 (19.7) | 118 (83.1) | 117 (84.2) |
| Omeprazole | 21 (16.7) | 6 (6.8) | 40 (31.0) | 40 (31.5) | 17 (10.1) | 13 (8.6) | 44 (31.0) | 43 (30.9) |
| Lansoprazole | 15 (11.9) | 6 (6.8) | 34 (26.4) | 34 (26.8) | 16 (9.5) | 13 (8.6) | 48 (33.8) | 48 (34.5) |
| Pantoprazole | 1 (0.8) | 1 (1.1) | 4 (3.1) | 4 (3.1) | 1 (0.6) | 0 (0.0) | 6 (4.2) | 6 (4.3) |
| Rabeprazole | 5 (4.0) | 2 (2.3) | 6 (4.7) | 6 (4.7) | 2 (1.2) | 0 (0.0) | 4 (2.8) | 4 (2.9) |
| Esomeprazole | 8 (6.3) | 6 (6.8) | 16 (12.4) | 16 (12.6) | 3 (1.8) | 2 (1.3) | 12 (8.5) | 12 (8.6) |
| H ₂ RAs, <i>n</i> (%) ^a | | | | | | | | |
| Any H ₂ Ra | 0 (0.0) | 0 (0.0) | 1 (0.8) | 1 (0.8) | 4 (2.4) | 1 (0.7) | 6 (4.2) | 6 (4.3) |
| Ranitidine | 0 (0.0) | 0 (0.0) | 1 (0.8) | 1 (0.8) | 4 (2.4) | 1 (0.7) | 5 (3.5) | 5 (3.6) |
| Famotidine | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.7) | 1 (0.7) |
| Over-the-counter H ₂ RA | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (1.8) | 2 (1.3) | 2 (1.4) | 2 (1.4) |
| Prokinetics, <i>n</i> (%) ^a | | | | | | | | |
| Any prokinetic | 6 (4.8) | 4 (4.5) | 8 (6.2) | 7 (5.5) | 5 (3.0) | 3 (2.0) | 7 (4.9) | 7 (5.0) |
| Domperidone | 5 (4.0) | 3 (3.4) | 5 (3.9) | 4 (3.1) | 3 (1.8) | 1 (0.7) | 6 (4.2) | 6 (4.3) |
| Metoclopramide | 1 (0.8) | 1 (1.1) | 3 (2.3) | 2 (1.6) | 2 (1.2) | 2 (1.3) | 1 (0.7) | 1 (0.7) |
| Any reflux-related drug, <i>n</i> (%) ^a | 51 (40.5) | 21 (23.9) | 106 (82.2) | 105 (82.7) | 43 (25.6) | 31 (20.4) | 125 (88.0) | 124 (89.2) |
| Other prescribed drugs, <i>n</i> ^b | | | | | | | | |
| Alginates | 12 | 4 | 11 | 11 | 12 | 9 | 13 | 13 |
| Antispasmodics (e.g. dicycloverine) | 2 | 2 | 2 | 1 | 0 | 0 | 0 | 0 |
| Chelates (e.g. sucralfate) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other ulcer-healing drugs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mucogel | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asilone | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 |
| Non-gastrointestinal | 4 | 4 | 3 | 1 | 1 | 0 | 0 | 0 |
| Anti-nausea | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
| Anti-motility | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 |
| Over the counter – not prescribed | 0 | 0 | 0 | 0 | 3 | 2 | 0 | 0 |

a Percentage is for responders completing the relevant section of the questionnaire.

b More than one prescription per person possible.

TABLE 46 Follow-up at the time point equivalent to 5 years after surgery: medications

| Medication | Randomised participants | | | | Preference participants | | | |
|--|-------------------------|--------------|--------------|--------------|-------------------------|--------------|---------------|---------------|
| | Surgical | | Medical | | Surgical | | Medical | |
| | ITT | PP | ITT | PP | ITT | PP | ITT | PP |
| Number randomised/allocated | 178 | 111 | 179 | 169 | 261 | 218 | 192 | 189 |
| Number of responders | 127 | 90 | 119 | 116 | 176 | 158 | 136 | 133 |
| PPIs, <i>n</i> (%) ^a | | | | | | | | |
| Any PPI | 55 (43.3) | 23 (25.6) | 98 (82.4) | 97 (83.6) | 48 (27.3) | 36 (22.8) | 116 (85.3) | 113 (85.0) |
| Omeprazole | 24 (18.9) | 10 (11.1) | 44 (37.0) | 43 (37.1) | 22 (12.5) | 15 (9.5) | 48 (35.3) | 46 (34.6) |
| Lansoprazole | 16 (12.6) | 5 (5.6) | 31 (26.1) | 31 (26.7) | 18 (10.2) | 15 (9.5) | 45 (33.1) | 45 (33.8) |
| Pantoprazole | 1 (0.8) | 1 (1.1) | 2 (1.7) | 2 (1.7) | 0 (0.0) | 0 (0.0) | 7 (5.1) | 7 (5.3) |
| Rabeprazole | 3 (2.4) | 2 (2.2) | 4 (3.4) | 4 (3.4) | 0 (0.0) | 0 (0.0) | 2 (1.5) | 2 (1.5) |
| Esomeprazole | 9 (7.1) | 6 (6.7) | 17 (14.3) | 17 (14.7) | 7 (4.0) | 6 (3.8) | 12 (8.8) | 11 (8.3) |
| H ₂ RAs, <i>n</i> (%) ^a | | | | | | | | |
| Any H ₂ RA | 0 (0.0) | 0 (0.0) | 2 (1.7) | 2 (1.7) | 3 (1.7) | 2 (1.3) | 6 (4.4) | 6 (4.5) |
| Ranitidine | 0 (0.0) | 0 (0.0) | 1 (0.8) | 1 (0.9) | 3 (1.7) | 2 (1.3) | 5 (3.7) | 5 (3.8) |
| Famotidine | 0 (0.0) | 0 (0.0) | 1 (0.8) | 1 (0.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Over-the-counter H ₂ RA | 1 (0.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 4 (2.3) | 1 (0.6) | 4 (2.9) | 4 (3.0) |
| Prokinetics, <i>n</i> (%) ^a | | | | | | | | |
| Any prokinetic | 6 (4.7) | 5 (5.6) | 5 (4.2) | 4 (3.4) | 8 (4.5) | 6 (3.8) | 5 (3.7) | 4 (3.0) |
| Domperidone | 5 (3.9) | 4 (4.4) | 4 (3.4) | 3 (2.6) | 4 (2.3) | 2 (1.3) | 4 (2.9) | 3 (2.3) |
| Metoclopramide | 1 (0.8) | 1 (1.1) | 2 (1.7) | 1 (0.9) | 3 (1.7) | 3 (1.9) | 1 (0.7) | 1 (0.8) |
| Any reflux-related drug, <i>n</i> (%) ^a | 56 (44.1) | 24 (26.7) | 98 (82.4) | 97 (83.6) | 49 (27.8) | 37 (23.4) | 121 (89.0) | 118 (88.7) |
| Other prescribed drugs, <i>n</i> ^b | | | | | | | | |
| Alginates | 11 | 3 | 11 | 11 | 12 | 9 | 15 | 15 |
| Antispasmodics (e.g. dicycloverine) | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 |
| Chelates (e.g. sucralfate) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other ulcer-healing drugs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mucogel | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asilone | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-gastrointestinal | 1 | 1 | 3 | 1 | 1 | 0 | 1 | 1 |
| Anti-nausea | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Anti-motility | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Over the counter – not prescribed | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |

a Percentage is for responders completing the relevant section of the questionnaire.

b More than one prescription per person possible.